Archive for June, 2010

Smoking Cannabis is a Link to Ancient History

Thursday, June 17th, 2010

The practice of smoking cannabis has probably been around since pre-historic times. There is strong evidence that the plant was extensively cultivated about 6,000 years ago in North Eastern Asia, primarily used for its fiber. Records of medicinal use and physiological effects are found in the earliest pharmacopoeia in existence, attributed to Emperor Shen Nung (2,000 BC). Cannabis most likely diffused from Asia to Persia, India, and other parts of the Middle East before entering Africa and Western Europe. Muslim and Persian trade routes probably introduced cannabis or dagga to Africa during the first few centuries AD. Interestingly, cannabis smoking wasn’t documented in Jamaica until about 1807, after the British empire brought in slaves from India and Africa.

Researchers recently found the 2,700 year-old grave of a shaman that contained about 789 grams of cannabis flower tops. They speculate that the cannabis was used for ritual or medicinal properties. This was a rare find, but archaeologists also have found other evidence of ancient cannabis smoking. Ornate “smoking bowls” have been found at other sites. These vary greatly in design, intricacy, and often contain ancient cannabis resin. Such bowls have been found throughout Africa. It is also thought that tobacco smoking spread quickly in Europe because humans were already familiar with smoking cannabis.

Methods for smoking cannabis have been developed over thousands of years. Early implements worked similarly to the so called Persian “hubble bubble” or hookah. Ancient societies made waterpipes from gourds, animal horns, earthernwares, and even straight out of the ground using a “smoking bowl” and a tube or reed. The modern age offers something new: vaporizer technology. Vaporizers are the result of thousands of years of humans exploring new and better methods for the use of cannabis.

Since the advent of vaporizers the inadequacies of smoking have become more apparent. Vaporizers basically pass ‘hot air’ over the plant material to make a mist or steam. In addition to reducing the exposure to smoke, vaporizers are a more efficient delivery system for cannabinoids.

Take the example of a cannabis cigarette or joint which contains 1 gram (1,000mg) of cannabis with 5 percent CBD (cannabidiol) by weight, or about 50mg of CBD. Upon lighting the cigarette, cannabinoids begin to be destroyed by burning and lost through side stream smoke. Vaporizers can reduce much of this flame-related cannabinoid loss. From that 50mg, some 11.5mg will be delivered to the body through smoking. Research has shown that vaporizers can recover up to 99.5 percent of cannabinoids. However, some loss cannot be prevented, as only some of the CBD is absorbed by the lungs and the rest is exhaled. It is unlikely that cigarettes, vaporizers, or hookahs can change the amount absorbed through the lungs. Scientists aren’t sure how much is exhaled but some estimate it at 30 to 80 percent.

As cannabis re-enters mainstream medicine, vaporizers are beginning to be accepted in hospitals and have been used in recent clinical trials exploring the medical benefits of cannabis. Finding efficient non-smoking alternatives to deliver cannabinoids may be key to gaining widespread acceptance in modern medicine.

Sources: Li, Hui-Lin. The Origin and use of cannabis in Eastern Asia: Their linguistic-cultural implications. Cannabis and Culture, 1975, pgs 51-62.

Jones, Lovinger. The Marijuana Question. 1985, Supplement A pg 463.

Pomahacova et al. Cannabis Smoke Condensate III: The cannabinoid content of vaporised Cannabis Sativa. Inhalation Toxicology 2009, 1-5, iFirst.

Russo et al. Phytochemical and genetic analysis of ancient cannabis from central Asia. Journal of Experimental Botany, Vol. 59, No. 15, pp. 4171–4182, 2008

**This articel first appeared in the West Coast Leaf Newspaper January 19, 2010.

Are Cannabinoids the Next Generation of Bone Drugs?

Friday, June 11th, 2010

The original version of this article first appeared in the Lab Bench Science Column of the West Coast Leaf NewsPaper on June 4th 2010.

The Lab Bench

By Jahan Marcu

A research team from the School of Medicine at Temple University, Philadelphia, presented their preliminary cannabinoid and bone data at a scientific meeting in Anaheim, CA in April. Our results add to a growing body of scientific evidence, suggesting a prominent role for the endocannabinoid system in bone development.  For the last year, researchers have been trying to reproduce and build upon previous work on cannabinoids and bone, specifically, by characterizing the effects of removing the CB1 and CB2 receptors from mice.

Few labs have published new discoveries regarding cannabis and bone. However, those that have are surprising so far. Some findings are so profound that the upcoming International Cannabinoid Research Society (ICRS) meeting will have a special symposium to discuss the bone data produced by just a few laboratories.

Research shows that bone cells have cannabinoid receptors and produce endocannabinoids. Bone cells express a lot of CB2 receptors and nerves that traverse our bones produce CB1 receptors. The `anti-cannabinoid’ receptor, GPR55, is also expressed in bone.

These receptors appear to work together to regulate bone health. Some clinical evidence supports the role of cannabinoids in various diseases. The Clinical Endocannabinoid Deficiency (Russo 2004) is thought to underlie many treatment- resistant conditions such as irritable bowel syndrome, fibromyalgia, and chronic pain. Recently, CB1 receptor mutations were linked to migraines, bi-polar disorder, and major depression (Monteleone 2010).

Now CB2 receptor mutations may be linked to lower human bone density and hand-bone strength. Research from Japan and France shows that mutations correlate to osteoporosis in post-menopausal women. The two studies looked at 2,626 elderly adults with and without osteoporosis. A study out in Russia analyzed the hand-bone strength of 574 adults and found that those with CB2 receptor muta- tions had weaker hand-bone strength (Yamada 2007, Karsak 2005, 2009). These all suggest that a less functional receptor is related to poor bone health.

Researchers have been studying how the body responds to traumatic brain injuries (TBI). When TBI occurs in a mouse, endocannabinoids are made and new bone is formed. Thus, cannabinoids may enhance the healing of bones in some instances such as fractures.

Genetically modified mice without the cannabinoid receptors have a deregulated skeleton. Depending on genetic makeup, the animals make too much or too little bone. So, research has shown that cannabinoids can both increase and decrease bone mass. However, all mice without cannabinoid receptors eventually develop severe osteoporosis (Bab 2008).

Plant cannabinoids such as CBDV, CBG, CBN, THC, and THCV may increase the number of bone stem cells in rats (Scutt 2007). Conversely, Anandamide has been shown to increase bone turnover by acti- vating osteoclasts, the cells that remodel or dissolve bone. CBD can inhibit osteoclasts. The infamous diet drug Rimonabandt, or SR141716A, is thought to prevent bone loss in mice by activating GPR55, not the CB1 receptor. Additionally, derivatives like WIN55,212 and some JWH compounds appear to severely inhibit osteoclasts from remodeling bone. Researchers have already speculated that cannabinoids represent a new generation of drugs that could treat a variety of bone diseases. For more information check out this recent review of the scientific literature, which discusses the role of the endocannabinoid system in bone disease and pathology.